Biocon on Friday said that its board has given an in-principle approval for the merger of the clinical research arm Clinigene with its parent company Syngene in a bid to streamline its integrated services. Syngene is looking at going public in FY15. ?The rationale is to strengthen the integrated services platform internally,? Syngene International director Peter Bains said.
Research arms to be merged
Biocon on Friday said that its board has given an in-principle approval for the merger of the clinical research arm Clinigene with its parent company Syngene in a bid to streamline its integrated services.
